Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | FAAH | O00519 | 2/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.62 |
| ▸ | PPARA | Q07869 | 2/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | ADH1B | P00325 | 1/20 | 0.52 |
| ▸ | ADH1C | P00326 | 1/20 | 0.52 |
| ▸ | ADH1A | P07327 | 1/20 | 0.52 |
| ▸ | ADH4 | P08319 | 1/20 | 0.52 |
| ▸ | ADH7 | P40394 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9480001 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL518802 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL9208641 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL6677501 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL11786437 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL23117202 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL518800 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL554166 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL22063916 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL296807 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226925-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2016-01-05 | — | — | US | claimed |
| US-8940729-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2015-01-27 | — | — | US | claimed |
| US-8912217-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-12-16 | — | — | US | claimed |
| WO-2025028468-A1 | HYDROPHILICITY-IMPARTING AGENT AND RESIN COMPOSITION CONTAINING SAME | 日油株式会社 | 2025-02-06 | — | — | WO | disclosed |
| EP-2871178-B1 | CATIONIC LIPID | KYOWA KIRIN CO LTD (JP) | 2020-12-23 | — | — | EP | disclosed |
| US-10342758-B2 | Cationic lipid | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-10342758-B2 | Cationic lipid | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| EP-3275448-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-9226925-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150174261-A1 | CATIONIC LIPID | KYOWA KIRIN CO., LTD. (JP) | 2015-06-25 | — | — | US | disclosed |
| US-20150174261-A1 | CATIONIC LIPID | KYOWA KIRIN CO., LTD. (JP) | 2015-06-25 | — | — | US | disclosed |
| US-8846766-B2 | Abuse-deterrent methadone for the safe treatment of drug abuse and pain relief | PISGAH LABORATORIES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8716278-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716337-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8653065-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653106-B2 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| WO-2014007398-A1 | CATIONIC LIPID | 協和発酵キリン株式会社 (JP) | 2014-01-09 | — | — | WO | disclosed |
| US-20130338229-A1 | Abuse-Deterrent Methadone for the Safe Treatment of Drug Abuse and Pain Relief | Pisgah National Laboratories, Inc. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8586575-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120028960-A1 | ABUSE DETERRENT AND ANTI-DOSE DUMPING PHARMACEUTICAL SALTS USEFUL FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | PISGAH LABORATORIES, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338229-A1 | Abuse-Deterrent Methadone for the Safe Treatment of Drug Abuse and Pain Relief | OPRM1, OGFR, OPRK1 | TSHR 2195/4885ALDH1A1 469/4885FAAH 1334/4885 |
| US-10342758-B2 | Cationic lipid | LIPA, LCLAT1, RNASEH1 | TSHR 1013/4885ALDH1A1 3766/4885FAAH 969/4885 |
| US-20120028960-A1 | ABUSE DETERRENT AND ANTI-DOSE DUMPING PHARMACEUTICAL SALTS USEFUL FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | COMT, SLC6A3, SLC6A2 | TSHR 2160/4885ALDH1A1 235/4885FAAH 676/4885 |
| US-20150174261-A1 | CATIONIC LIPID | LIPA, LCLAT1, RNASEH1 | TSHR 1013/4885ALDH1A1 3766/4885FAAH 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.